Study S001717
A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)
Registration
Registered primary outcomes
- Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score [From baseline (week 0) to week 104]
Linked records (11)
Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
| Record | Title | Year | Design | Identifiers | Link basis |
|---|---|---|---|---|---|
| R0005459 | Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease. Scheltens P, Alzheimer's & dementia (New York, N. Y.) | 2026 | Randomized trial | PMID 41522368DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0010697 | Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Cummings JL, Lancet (London, England) | 2026 | Randomized trial | PMID 41865758DOI | cites ClinicalTrials.gov:NCT04777396; registry reference DERIVED:41865758 |
| R0007201 | evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Cummings JL, Alzheimer's research & therapy | 2025 | Randomized trial | PMID 39780249DOI | cites ClinicalTrials.gov:NCT04777396; registry reference DERIVED:39780249 |
| R0007283 | evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease Cummings JL, Research Square | 2024 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0017925 | Reasons for screening failure in the evoke and evoke+ trials of semaglutide for early AD Sano M, Alzheimer's & dementia : the journal of the Alzheimer's Association | 2024 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0018118 | Investigating the effects of semaglutide in early Alzheimer’s disease using single‐cell transcriptomics and proteomics – rationale and design Johannsen P, Alzheimer's & dementia : the journal of the Alzheimer's Association | 2024 | Protocol | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0048823 | Baseline Characteristics from Evoke and Evoke+: Two Phase 3 Randomized Placebo-controlled Trials of Oral Semaglutide in Patients with Early Alzheimer’s Disease (P11-9.013) Philip Scheltens, Neurology | 2024 | Randomized trial | PMID 39977949DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0048854 | Preliminary baseline characteristics from evoke and evoke+: two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer’s disease Philip Scheltens, Arquivos de Neuro-Psiquiatria | 2024 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0053377 | Regional differences in baseline demographic and clinical characteristics from the evoke and evoke+ trials of semaglutide for early Alzheimer’s disease Wiesje M. van der Flier, Alzheimer s & Dementia | 2024 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0048974 | Investigating changes in fluid biomarkers in early Alzheimer’s disease: design of plasma biomarker analyses and a cerebrospinal fluid sub‐study in the evoke and evoke+ trials of semaglutide versus placebo Jeffrey L. Cummings, Alzheimer s & Dementia | 2022 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |
| R0053617 | evoke and evoke+: design of two large‐scale, double‐blind, placebo‐controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease Alireza Atri, Alzheimer s & Dementia | 2022 | Randomized trial | DOI | cites ClinicalTrials.gov:NCT04777396 |